

FILE 'REGISTRY' ENTERED AT 15:48:20 ON 08 SEP 2009

EXP GANGLIOSIDE/CN

EXP GANGLIOSIDE GD3/CN

L1 2 S E3

FILE 'STNGUIDE' ENTERED AT 15:49:12 ON 08 SEP 2009

FILE 'HCAPLUS' ENTERED AT 15:50:22 ON 08 SEP 2009

L2 117 S L1/THU

L3 632962 S CHOLESTEROL OR HYPERCHOLESTEROLEM? OR ATHEROSCLEROSIS OR INFL

L4 27 S L2 AND L3

L5 18 S L4 AND (PY<2004 OR AY<2004 OR PRY<2004)

```
=> file registry
COST IN U.S. DOLLARS                SINCE FILE      TOTAL
                                     ENTRY      SESSION
FULL ESTIMATED COST                0.22          0.22
```

FILE 'REGISTRY' ENTERED AT 15:48:20 ON 08 SEP 2009
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2009 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

```
STRUCTURE FILE UPDATES:    7 SEP 2009  HIGHEST RN 1181105-91-8
DICTIONARY FILE UPDATES:  7 SEP 2009  HIGHEST RN 1181105-91-8
```

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.

Please note that search-term pricing does apply when
 conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
 predicted properties as well as tags indicating availability of
 experimental property data in the original document. For information
 on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stdoc/properties.html>

```
=> exp ganglioside/cn
E1      1      GANGLIO-N-TETRAOSYLCERAMIDE/CN
E2      1      GANGLIO-N-TRIAOSYLCERAMIDE/CN
E3      1 -->  GANGLIOSIDE/CN
E4      1      GANGLIOSIDE AGAL-(LACNAC)2-GM1/CN
E5      1      GANGLIOSIDE 3',6'-ISOLD1/CN
E6      1      GANGLIOSIDE 3'-ISOLM1/CN
E7      1      GANGLIOSIDE 3'-LM1/CN
E8      1      GANGLIOSIDE 3'-NLM1/CN
E9      1      GANGLIOSIDE 6' GM3/CN
E10     1      GANGLIOSIDE 6'-GM2/CN
E11     1      GANGLIOSIDE 6'-LM1/CN
E12     1      GANGLIOSIDE 6'-NLM1/CN

=> exp ganglioside GD3/cn
E1      1      GANGLIOSIDE GD2, N'-ACETYL-N-GLYCOLOYL-/CN
E2      1      GANGLIOSIDE GD2, N,N'-DIACETYL-/CN
E3      2 -->  GANGLIOSIDE GD3/CN
E4      1      GANGLIOSIDE GD3 (SYNTHETIC)/CN
E5      1      GANGLIOSIDE GD3 B1,4-N-ACETYL GALACTOSAMINYLTRANSFERASE/
CN
E6      1      GANGLIOSIDE GD3 ACETYL GALACTOSAMINYLTRANSFERASE/CN
E7      1      GANGLIOSIDE GD3 AMIDE/CN
E8      1      GANGLIOSIDE GD3 LACTONE I/CN
E9      1      GANGLIOSIDE GD3 LACTONE II/CN
E10     1      GANGLIOSIDE GD3 SYNTHASE/CN
E11     1      GANGLIOSIDE GD3 SYNTHASE (HUMAN CLONE PAMO-GD3)/CN
E12     1      GANGLIOSIDE GD3 SYNTHETASE/CN
```

```
=> s e32
'E32' NOT FOUND
```

The E# entered is not currently defined.

=> s e3

L1 2 "GANGLIOSIDE GD3"/CN

=> d l1 scan

L1 2 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Ceramide, 1-O-[O-(N-acetyl- α -neuraminosyl)-(2 \rightarrow 8)-O-(N-acetyl- α -neuraminosyl)-(2 \rightarrow 3)-O- β -D-galactopyranosyl-(1 \rightarrow 4)- β -D-glucopyranosyl]-
MF Unspecified
CI COM, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L1 2 ANSWERS REGISTRY COPYRIGHT 2009 ACS on STN
IN Ganglioside GD3
MF Unspecified
CI COM, MAN

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

ALL ANSWERS HAVE BEEN SCANNED

=> d l1

L1 ANSWER 1 OF 2 REGISTRY COPYRIGHT 2009 ACS on STN
RN 104443-61-0 REGISTRY
ED Entered STN: 27 Sep 1986
CN Ceramide, 1-O-[O-(N-acetyl- α -neuraminosyl)-(2 \rightarrow 8)-O-(N-acetyl- α -neuraminosyl)-(2 \rightarrow 3)-O- β -D-galactopyranosyl-(1 \rightarrow 4)- β -D-glucopyranosyl]- (CA INDEX NAME)

OTHER NAMES:

CN Ac-GD3
CN CD 60a antigen
CN Ganglioside GD3
CN Ganglioside GD3, N,N'-diacetyl-
CN Ganglioside Glac2
CN GD3
CN Glac2
CN II3(NeuAc)2-LacCer
CN LMG 4
CN N,N'-Diacetylganglioside GD3
CN NeuAc-GD3
DR 154362-30-8
MF Unspecified
CI COM, MAN
SR CA

LC STN Files: AGRICOLA, BIOSIS, CA, CAPLUS, CASREACT, CIN, PROMT,
TOXCENTER, USPAT2, USPATFULL

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

368 REFERENCES IN FILE CA (1907 TO DATE)
17 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA
368 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> file stnguide
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
7.88	8.10

FULL ESTIMATED COST

FILE 'STNGUIDE' ENTERED AT 15:49:12 ON 08 SEP 2009
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Sep 4, 2009 (20090904/UP).

=> file hcaplus
COST IN U.S. DOLLARS

SINCE FILE	TOTAL
ENTRY	SESSION
0.14	8.24

FULL ESTIMATED COST

FILE 'HCAPLUS' ENTERED AT 15:50:22 ON 08 SEP 2009
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 8 Sep 2009 VOL 151 ISS 11
FILE LAST UPDATED: 7 Sep 2009 (20090907/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Jun 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Jun 2009

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

The ALL, BIB, MAX, and STD display formats in the CA/CAPlus family of databases have been updated to include new citing references information. This enhancement may impact record import into database management software. For additional information, refer

to NEWS 9.

=> s 11/thu

1547 L1
1163318 THU/RL
L2 117 L1/THU
(L1 (L) THU/RL)

=> s cholesterol or hypercholesterolem? or atherosclerosis or inflammation or inflammatory or allergic or allergy

202287 CHOLESTEROL
19913 HYPERCHOLESTEROLEM?
68579 ATHEROSCLEROSIS
218099 INFLAMMATION
238528 INFLAMMATORY
44333 ALLERGIC
56968 ALLERGY
L3 632962 CHOLESTEROL OR HYPERCHOLESTEROLEM? OR ATHEROSCLEROSIS OR INFLAMMATION OR INFLAMMATORY OR ALLERGIC OR ALLERGY

=> s 12 and 13

L4 27 L2 AND L3

=> s 14 and (PY<2004 or AY<2004 or PRY<2004)

24036163 PY<2004
4804060 AY<2004
4277077 PRY<2004
L5 18 L4 AND (PY<2004 OR AY<2004 OR PRY<2004)

=> file stnguide

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.85	11.09

FILE 'STNGUIDE' ENTERED AT 15:50:28 ON 08 SEP 2009
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Sep 4, 2009 (20090904/UP).

=> d 15 1-18 ti abs bib

YOU HAVE REQUESTED DATA FROM FILE 'HCAPLUS' - CONTINUE? (Y)/N:y

L5 ANSWER 1 OF 18 HCAPLUS COPYRIGHT 2009 ACS on STN
T1 Formulations for mediating inflammatory bowel disorders
AB The invention provides formulations and methods for mediating inflammation, in particular an inflammatory bowel disorder such as necrotizing enterocolitis. Further, the formulations are effective in lowering blood cholesterol and decreasing blood cholesterol absorption. The formulations comprise at least one ganglioside, which may be selected from the group consisting of: GD3, GM1, GM2, GM3, and GD1b. The invention provides a method of treating or

preventing inflammatory diseases, such as necrotizing enterocolitis by delivery of at least one ganglioside to a subject in need thereof. Supplementation of foods or liqs. with gangliosides, for example infant formula or infant foods, can be employed according to the invention.

AN 2007:815148 HCAPLUS <<LOGINID:20090908>>
 DN 147:197354
 TI Formulations for mediating inflammatory bowel disorders
 IN Clandinin, Michael Thomas; Park, Eek J.
 PA Mti Meta Tech Inc., Can.
 SO U.S. Pat. Appl. Publ., 39pp., Cont.-in-part of U.S. Ser. No. 551,789
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20070173480	A1	20070726	US 2007-622858	20070112
	WO 2004087173	A2	20041014	WO 2004-CA375	20040312 <---
	WO 2004087173	A3	20041125		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	US 20060276430	A1	20061207	US 2004-551789	20040312 <---
PRAI	US 2004-551789	A2	20040312		
	WO 2004-CA375	W	20040312		
	US 2003-404095	A	20030402	<---	

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

L5 ANSWER 2 OF 18 HCAPLUS COPYRIGHT 2009 ACS on STN
 TI Cloning and sequences of genetically engineered proteases that cleave target molecules for diagnosis or treatment of human diseases
 AB The present invention provides a disease treatment method by applying a medicament comprising a protease with defined target substrate specificity that enables hydrolysis of specific peptide bonds within the substrate related to such disease. This invention aims to create mutated proteases that target proteins or enzymes associated with disease (several dozen claimed mols.), for the purpose of hydrolysis-mediated alteration of cellular behavior aiding in diagnosis or treatment of human diseases. Specificity determining regions (SDR) from selected proteases were randomly inserted into a protein scaffold, enabling the protein scaffold to perform hydrolysis upon the SDR-determined substrate. Claimed are the sequences of human trypsin I, Bacillus subtilis subtilisin E, human pepsin A, and human caspase-7. Use of the modified trypsin protease upon tumor necrosis factor- α , serum proteins and VEGF, as well as anal. of corresponding cytotoxicity, is presented. The proteases with such a defined specificity can further be used for related therapeutic or diagnostic purposes.
 AN 2005:735080 HCAPLUS <<LOGINID:20090908>>
 DN 143:206400
 TI Cloning and sequences of genetically engineered proteases that cleave target molecules for diagnosis or treatment of human diseases
 IN Haupts, Ulrich; Koltermann, Andre; Scheidig, Andreas; Votsmeier, Christian; Kettling, Ulrich; Coco, Wayne Michael

PA Germany
 SO U.S. Pat. Appl. Publ., 217 pp., Cont.-in-part of U.S. Ser. No. 872,198.
 CODEN: USXXCO
 DT Patent
 LA English
 FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20050175581	A1	20050811	US 2004-21951	20041222 <--
	EP 1531179	A1	20050518	EP 2003-25871	20031111 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	AU 2004249903	A1	20041229	AU 2004-249903	20040618 <--
	AU 2004249903	B2	20090604		
	AU 2004249904	A1	20041229	CA 2004-249904	20040618 <--
	CA 2529589	A1	20041229	CA 2004-2529589	20040618 <--
	CA 2529659	A1	20041229	CA 2004-2529659	20040618 <--
	WO 2004113521	A1	20041229	WO 2004-EP51172	20040618 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	WO 2004113522	A1	20041229	WO 2004-EP51173	20040618 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	US 20050002897	A1	20050106	US 2004-872198	20040618 <--
	EP 1633865	A1	20060315	EP 2004-741841	20040618 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	EP 1633866	A1	20060315	EP 2004-741842	20040618 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	JP 2006527590	T	20061207	JP 2006-516170	20040618 <--
	JP 2006527738	T	20061207	JP 2006-516171	20040618 <--
FRAI	EP 2003-13819	A	20030618	<--	
	EP 2003-25851	A	20031110	<--	
	EP 2003-25871	A	20031111	<--	
	US 2003-524960P	P	20031125	<--	
	EP 2004-3058	A	20040211		
	US 2004-543518P	P	20040211		
	US 2004-872198	A2	20040618		
	WO 2004-EP51172	W	20040618		
	WO 2004-EP51173	W	20040618		

OSC.G 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L5 ANSWER 3 OF 18 HCAPLUS COPYRIGHT 2009 ACS on STN

TI Deimmunized fusion proteins comprising CD3-binding domain and Ig binding domain for diagnosis and treatment of cancer, inflammation, infection, (auto)immune disease or allergy

AB The present invention provides a cytotoxically active CD3 specific binding construct comprising a first domain specifically binding to human CD3 and an Ig-derived second binding domain. Furthermore, a nucleic acid sequence encoding a CD3 specific binding construct of the invention is provided. The Ig-derived binding domain comprises an antigen-interaction site with a specificity for mol. such as EpCAM, CCR5, CD19, Her-2, Her-2/neu, Her-3, Her-4, EGFR, PSMA, CEA, MUC-1, MUC2, MUC3, MUC4, MUC5AC, MUC5a, MUC7, β hCG, Lewis Y, CD20, CD33, CD30, GD3, 9-O-acetyl GD3, GM2, Globo H, fucosyl GM1, polySA, GD2, carboanhydrase IX, CD44v6, sonic Hedgehog, Wue-1, etc. Further aspects of the invention are vectors and host cells comprising said nucleic acid sequence, a process for the production of the construct of the invention and composition comprising said construct. The invention also provides the use of said constructs for the preparation of pharmaceutical compns. for the treatment of particular diseases, a method for the treatment of particular diseases and a kit comprising the binding construct of the invention.

AN 2005:395357 HCAPLUS <<LOGINID::20090908>>

DN 142:446010

TI Deimmunized fusion proteins comprising CD3-binding domain and Ig binding domain for diagnosis and treatment of cancer, inflammation, infection, (auto)immune disease or allergy

IN Hofmeister, Robert; Kohleisen, Birgit; Lenkkeri-Schuetz, Ulla; Itin, Christian; Baeuerle, Patrick; Carr, Francis J.; Hamilton, Anita A.; Williams, Stephen

PA Micromet A.-G., Germany

SO PCT Int. Appl., 639 pp. CODEN: P1XXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2005040220	A1	20050506	WO 2004-EP11646	20041015 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004283850	A1	20050506	AU 2004-283850	20041015 <--
	CA 2542239	A1	20050506	CA 2004-2542239	20041015 <--
	EP 1673398	A1	20060628	EP 2004-790488	20041015 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
	CN 1867586	A	20061122	CN 2004-80030150	20041015 <--
	CN 100453556	C	20090121		
	BR 2004015457	A	20061205	BR 2004-15457	20041015 <--
	ZA 2006001699	A	20070530	ZA 2006-1699	20041015 <--
	JP 2007537714	T	20071227	JP 2006-534709	20041015 <--
	NZ 546173	A	20090430	NZ 2004-546173	20041015 <--
	MX 2006004035	A	20060831	MX 2006-4035	20060410 <--
	IN 2006CN01280	A	20070629	IN 2006-CN1280	20060413 <--

NO	2006002117	A	20060703	NO	2006-2117	20060511 <--
US	20090022738	A1	20090122	US	2006-572740	20061204 <--
PRAI	EP	2003-23581	A	20031016	<--	
WO	2004-EP11646	W	20041015			

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
 RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 4 OF 18 HCAPLUS COPYRIGHT 2009 ACS on STN
 TI Antibodies conjugated with phagocytic marker for enhancing phagocytosis against autoimmune disease, infection, cancer and others
 AB The present invention provides a system for enhancing clearance or destruction of undesirable cells or noncellular mol. entities by tagging such cells or noncellular mol. entities with a marker that targets the cells or noncellular mol. entities for phagocytosis (phagocytic marker). The target cells can be, for example, endothelial cells, tumor cells, leukocytes, or virus-infected cells. In certain embodiments of the invention the tagging is accomplished by administering a composition comprising an antibody or ligand linked to the phagocytotic marker, wherein the antibody or ligand binds to a cell type specific marker present on or in the cell surface of a target cell. In preferred embodiments of the invention, the phagocytic marker comprises phosphatidylserine or a group derived from phosphatidylserine, thrombospondin-1, annexin I, or a derivative of any of these.

AN 2005:182810 HCAPLUS <<LOGINID:20090908>>
 DN 142:278750

TI Antibodies conjugated with phagocytic marker for enhancing phagocytosis against autoimmune disease, infection, cancer and others

IN Francois, Cedric; Olson, Paul; Deschatelets, Pascal; Machiels, Alec

PA Potentia Pharmaceuticals, Inc., USA

SO PCT Int. Appl., 173 pp.

CODEN: P1XXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2005019429	A2	20050303	WO 2004-US27245	20040823 <--
	WO 2005019429	A3	20060302		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

US	20050113297	A1	20050526	US	2004-923940	20040823 <--
PRAI	US	2003-497086P	P	20030822	<--	
	US	2003-514941P	P	20031028	<--	
	US	2003-523611P	P	20031119	<--	
	US	2003-524126P	P	20031121	<--	
	US	2003-524730P	P	20031124	<--	
	US	2004-547951P	P	20040226		
	WO	2004-US27245	A	20040823		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OS MARPAT 142:278750

OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
 RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 5 OF 18 HCAPLUS COPYRIGHT 2009 ACS on STN
 TI Human molecules or antibodies specific to human CD3 complex for diagnosis
 and treatment of proliferative, inflammatory, immune,
 autoimmune, infectious or allergic diseases
 AB The present invention provides a method for the preparation of a human binding
 mol., fragment or derivative thereof which specifically binds to the human CD3
 complex. The binding mols. are human, humanized or deimmunized antibodies
 or fragments; and are selected from a DNA or RNA library by a phage
 display method. The antibodies may comprise at least one further
 antigen-interaction-site and/or effector domain selected from EpCAM, CCR5,
 CD19, EphA2, HER-2 neu, HER-3, HER-4, EGFR, PSMA, CEA, MUC1, MUC2, MUC3,
 MUC4, MUC5, MUC7, B_hCG, Lewis-Y, CD20, CD33, CD30, ganglioside GD3,
 etc. These binding mols. or antibodies and fragments are useful for
 diagnosis and treatment of proliferative disease, tumor,
 inflammation, immune disease, autoimmune disease, infection, viral
 infection, allergy, parasitic infection or graft vs. host
 disease.

AN 2004:1059392 HCAPLUS <<LOGINID::20090908>>
 DN 142:36924

TI Human molecules or antibodies specific to human CD3 complex for diagnosis
 and treatment of proliferative, inflammatory, immune,
 autoimmune, infectious or allergic diseases
 IN Kufer, Peter; Raum, Tobias; Berry, Meera; Kischel, Roman; Mangold,
 Susanne; Krinner, Eva; Kohleisen, Birgit; Zeman, Steven; Itin, Christian;
 Baeuerle, Patrick

PA Micromet A.-G., Germany
 SO PCT Int. Appl., 350 pp.
 CODEN: PIXXD2

DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004106380	A2	20041209	WO 2004-EP5684	20040526 <--
	WO 2004106380	A3	20050623		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MM, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2004242845	A1	20041209	AU 2004-242845	20040526 <--
	CA 2523716	A1	20041209	CA 2004-2523716	20040526 <--
	EP 1629011	A2	20060301	EP 2004-739377	20040526 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK				
	IN 2005CN02915	A	20070914	IN 2005-CN2915	20051108 <--
PRAI	EP 2003-12132	A	20030531	<--	
	WO 2004-EP5684	W	20040526		

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 6 OF 18 HCAPLUS COPYRIGHT 2009 ACS on STN
 TI 36Fusion proteins comprising CD1d complex, α 2 microglobulin and antibody or fragment for targeting therapy of tumor, autoimmune disease, inflammation and infection
 AB The invention is directed to a compound comprising one or more CD1d complexes in association with an antibody specific for a cell surface marker. The CD1d complexes comprise a CD1d, a ss2-microglobulin mol., and may further comprise an antigen bound to the CD1d binding groove. The invention is further directed to methods of inhibiting or stimulating an immune response with the CD1d-antibody compds., in particular anti-tumor and autoimmunity responses.
 AN 2004:292071 HCAPLUS <<LOGINID::20090908>>
 DN 140:320040
 TI 36Fusion proteins comprising CD1d complex, α 2 microglobulin and antibody or fragment for targeting therapy of tumor, autoimmune disease, inflammation and infection
 IN Robert, Bruno; Donda, Alena; Cesson, Valerie; Mach, Jean-Pierre; Zauderer, Maurice
 PA Vaccinex, Inc., USA
 SO PCT Int. Appl., 152 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2004029206	A2	20040408	WO 2003-US30238	20030926 <--
	WO 2004029206	A3	20041007		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP	1413316	A1	20040428	EP 2002-405838	20020927 <--
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
CA	2502735	A1	20040408	CA 2003-2502735	20030926 <--
AU	2003275254	A1	20040419	AU 2003-275254	20030926 <--
EP	1551448	A2	20050713	EP 2003-759526	20030926 <--
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
IN	2005KN00523	A	20060127	IN 2005-KN523	20050329 <--
US	20060269540	A1	20061130	US 2006-529221	20060630 <--
IN	2007KN02053	A	20080801	IN 2007-KN2053	20070606 <--
PRAI	EP 2002-405838	A	20020927	<--	
	WO 2003-US30238	W	20030926	<--	
	IN 2005-KN523	A3	20050329		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
 RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 7 OF 18 HCAPLUS COPYRIGHT 2009 ACS on STN
 TI Antibodies produced by host cells tolerant to fucose-N-acetylglucosamine 1-6 α binding structure-recognizing lectins
 AB Disclosed is a process for producing an antibody composition with the use of

cells tolerant to a lectin recognizing a sugar chain structure in which an α -bond is formed between the 6-position of N-acetylglucosamine at the reducing end of an N-glycoside bond-type complex sugar chain and the 1-position of fucose; and cells usable in this process. The antibodies exhibit enhanced antibody-dependent cytotoxicity. The host cells have lower or defective carbohydrate modification-related proteins such as (1) GDP-fucose synthesizing enzyme proteins, (2) fucose-N-acetylglucosamine 1-6 α -binding structure-modifying enzyme proteins, and (3) GDP-fucose to Golgi body-transporting proteins, e.g. α -1,6-fucosyltransferase. The genes of these carbohydrate-modifying enzymes are destroyed by gene targeting, dominant neg. body introduction, mutation or mutagenesis, transcription and/or translation inhibition, and RNAi. Antibodies prepared by the method include human antibodies, humanized or chimeric antibodies, antibody fragments and IgGs. These antibodies are prepared for diagnosis, prevention and treatment of cancer, allergy, inflammation, autoimmune disease, circulation disease, viral infection and bacterial infection.

AN 2003:818543 HCAPLUS <<LOGINID:20090908>>
DN 139:322290

TI Antibodies produced by host cells tolerant to fucose-N-acetylglucosamine 1-6 α binding structure-recognizing lectins

IN Satoh, Mitsuo; Kamachi, Reiko; Kanda, Yutaka; Mori, Katsuhiko; Yamano, Kazuya; Kinoshita, Satoko; Iida, Shigeru

PA Kyowa Hakko Kogyo Co., Ltd., Japan

SO PCT Int. Appl., 297 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2003085118	A1	20031016	WO 2003-JP4502	20030409 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2481837	A1	20031016	CA 2003-2481837	20030409 <--
AU 2003236015	A1	20031020	AU 2003-236015	20030409 <--
US 20040132140	A1	20040708	US 2003-409616	20030409 <--
EP 1498490	A1	20050119	EP 2003-723096	20030409 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRAI JP 2002-106820	A	20020409 <--		
JP 2003-24685	A	20030131 <--		
WO 2003-JP4502	W	20030409 <--		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OSC.G 16 THERE ARE 16 CAPLUS RECORDS THAT CITE THIS RECORD (34 CITINGS)

RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 8 OF 18 HCAPLUS COPYRIGHT 2009 ACS on STN

TI Antibodies produced by cells tolerant to lectin recognizing 1-6 α -bond between N-acetylglucosamine and fucose for diagnosis and therapy in patients suffering from Fc γ RIIIa polymorphism

AB A drug containing, as the active ingredient, an antibody composition produced with

the use of cells tolerant to a lectin recognizing a sugar chain structure in which an α -bond is formed between the 6-position of N-acetylglucosamine at the reducing end of an N-glycoside bond-type complex sugar chain and the 1-position of fucose. This drug is appropriate for patients suffering from Fc γ RIIIa polymorphism who cannot be treated with a drug containing, as the active ingredient, an antibody composition produced from cells not tolerant to a lectin recognizing a sugar chain structure in which an α -bond is formed between the 6-position of N-acetylglucosamine at the reducing end of an N-glycoside bond-type complex sugar chain and the 1-position of fucose. Such chimeric antibodies specific to GD3, FGF8, CD20, and CCR4 were prepared for diagnosis, prevention and treatment of tumor, allergy, inflammation, autoimmune disease, circulation disorder, viral infection and bacterial infection.

AN 2003:818312 HCAPLUS <<LOGINID:20090908>>

DN 139:322285

TI Antibodies produced by cells tolerant to lectin recognizing 1-6 α -bond between N-acetylglucosamine and fucose for diagnosis and therapy in patients suffering from Fc γ RIIIa polymorphism

IN Nakamura, Kazuyasu; Shitara, Kenya; Hatanaka, Shigeki; Niwa, Rinpei; Okazaki, Akira

PA Kyowa Hakko Kogyo Co., Ltd., Japan

SO PCT Int. Appl., 214 pp.

CODEN: PIXXD2

DT Patent

LA Japanese

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2003084570	A1	20031016	WO 2003-JP4505	20030409 <--
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2481925	A1	20031016	CA 2003-2481925	20030409 <--
	AU 2003236019	A1	20031020	AU 2003-236019	20030409 <--
	EP 1502603	A1	20050202	EP 2003-723099	20030409 <--
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
	US 20050031613	A1	20050210	US 2003-409608	20030409 <--
PRAI	JP 2002-106951	A	20020409	<--	
	WO 2003-JP4505	W	20030409	<--	

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

RE.CNT 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 9 OF 18 HCAPLUS COPYRIGHT 2009 ACS on STN

TI Isolation and identification of buffalo milk gangliosides and their use for humanization of infant and other formulas

AB The present invention relates to gangliosides derived or isolated from buffalo milk, skimmed buffalo milk, buffalo milk serum or derivs. of either. Buffalo milk is reported to comprise gangliosides that are not contained in bovine milk, such as gangliosides that belong to the GM1-class. Furthermore, buffalo milk is found to comprise unknown gangliosides, denoted herein as ganglioside "F" and "L". Furthermore, the

invention reports that gangliosides are surprisingly found in fractions of isolation procedures that were so far not considered to comprise gangliosides. Finally, milk or milk serum from buffalo, for example as derived from mozzarella cheese production, contains specific gangliosides in the same amts. as human breast milk, which makes it suitable for humanization of infant and other formulas. Anti-inflammatory effects of buffalo milk gangliosides are also disclosed.

AN 2003:509876 HCAPLUS <<LOGINID:20090908>>

DN 139:68312

TI Isolation and identification of buffalo milk gangliosides and their use for humanization of infant and other formulas

IN Colarow, Ladislav; Turini, Marco; Berger, Alvin

PA Societe des Produits Nestle S.A., Switz.

SO Eur. Pat. Appl., 24 pp.

CODEN: EPXXDW

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	EP 1323424	A1	20030702	EP 2001-130614	20011227 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	WO 2003055497	A1	20030710	WO 2002-EP14876	20021220 <--
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	AU 2002361244	A1	20030715	AU 2002-361244	20021220 <--
	AU 2002361244	B2	20080807		
	EP 1461048	A1	20040929	EP 2002-796763	20021220 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
	NZ 534132	A	20061222	NZ 2002-534132	20021220 <--
	US 20050107311	A1	20050519	US 2004-498946	20040615 <--
PRAI	EP 2001-130614	A	20011227 <--		
	WO 2002-EP14876	W	20021220 <--		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

RE.CNT 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 10 OF 18 HCAPLUS COPYRIGHT 2009 ACS on STN

TI Inducing tolerance or immunomodulation using dendritic cells incubated with antigen

AB Disclosed is a method of altering immune responses using dendritic cells. One form of the method is a method of inducing immunol. tolerance in an individual, where type 2 dendritic cells are administered to an individual, and where the dendritic cells have been incubated with one or more antigens. Another form of the method involves altering an immune response, in which liposomes containing one or more antigens are administered to an individual, and where the liposomes are modified with surface-bound mols. that target the liposomes to type 2 dendritic cells. Another form of the method involves reducing immune responsiveness, where liposomes containing one or more antigens are administered to an individual and where the liposomes are modified with the surface bound mols. that target the

liposomes to type 1 dendritic cells or type 2 dendritic cells. Another form of the method is a method of enhancing immune responsiveness, where liposomes containing one or more antigens are administered to an individual, and where the liposomes are modified with surface-bound mols. that target the liposomes to mature type 1 dendritic cells. The antigens can be autoantigens, alloantigens, tumor antigens, and viral antigens, and can be in the form of carbohydrates, peptides, nucleic acids, and lipids. The liposome surface-bound mols. can be specific for CD11c+ and/or BDCA-1, which targets mature type 1 dendritic cells. Type 2 dendritic cells can be targeted by using surface-bound mols. specific for CD123, BDCA-2, and/or BDCA-4.

AN 2002:869052 HCAPLUS <<LOGINID:20090908>>

DN 137:336727

TI Inducing tolerance or immunomodulation using dendritic cells incubated with antigen

IN Waller, Edmund K.; Rosenthal, Hillary S.; Lonail, Sagar

PA Emory University, USA

SO PCT Int. Appl., 34 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002090510	A2	20021114	WO 2002-US14497	20020508 <--
	WO 2002090510	A3	20030410		
	WO 2002090510	A9	20040429		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TG, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2002305452	A1	20021118	AU 2002-305452	20020508 <--
	US 20050013810	A1	20050120	US 2004-477012	20040430 <--
PRAI	US 2001-289625P	P	20010508	<--	
	WO 2002-US14497	W	20020508	<--	

OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

L5 ANSWER 11 OF 18 HCAPLUS COPYRIGHT 2009 ACS on STN

TI Colostrum-based pharmaceutical compositions

AB A composition including colostrum or a colostrum-derived product and hyperimmune milk (HIM) or a hyperimmune milk-derived product, in amts. sufficient to provide a combined spectrum of pathogen-binding activity against a broad-spectrum of pathogenic organisms is described. For example, a test composition was prepared including 70% colostrum milk protein powder, 24% hyperimmune milk powder, 4% ganglioside-containing component, whey powder, lactose and 1.5% milk calcium. The test composition of the invention includes a combination of ingredients each of which has particular antimicrobial binding and/or anti-inflammatory activity which may combine to produce particular and unexpected clin. benefits in a broad range of diseases, including infection-associated diseases, and particularly gastrointestinal, inflammatory and bone related disorders. Such benefits are an unexpected result of the combination used.

AN 2002:391563 HCAPLUS <<LOGINID:20090908>>


DN 136:391021

TI Colostrum-based pharmaceutical compositions

IN Williams, Charles Edward; Hobman, Peter Graeme; Yarrow, Simon Stephen
 PA Fonterra Co-Operative Group Limited, N. Z.
 SO PCT Int. Appl., 43 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002040051	A1	20020523	WO 2001-NZ256	20011115 <--
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2002024240	A	20020527	AU 2002-24240	20011115 <--
	EP 1341554	A1	20030910	EP 2001-996393	20011115 <--
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	JP 2004517067	T	20040610	JP 2002-542423	20011115 <--
	HU 2004000589	A2	20040628	HU 2004-589	20011115 <--
	HU 2004000589	A3	20050628		
	CN 1299771	C	20070214	CN 2001-822044	20011115 <--
	US 20040047856	A1	20040311	US 2003-416831	20031008 <--
	US 20050220894	A1	20051006	US 2005-136575	20050525 <--
FRAI	NZ 2000-508234	A	20001115	<--	
	WO 2001-NZ256	W	20011115	<--	
	US 2003-416831	A3	20031008	<--	
OSC.G	2	THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)			
RE.CNT	3	THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD			
		ALL CITATIONS AVAILABLE IN THE RE FORMAT			

L5 ANSWER 12 OF 18 HCAPLUS COPYRIGHT 2009 ACS on STN
 TI Novel synthetic gangliosides
 GI



I

AB Disclosed are novel synthetic ganglioside comprising a modified sphingosine group represented by Structural Formula (I); Y is -O- or -NH-; X is =O or -H2; R1 and R2 are independently a substituted or unsubstituted straight chain or branched hydrocarbyl group, wherein the hydrocarbyl group optionally comprises -S-, -S(O)-, -SO2-, -O- or -NR- (each R is independently -H, an aliphatic group, a substituted aliphatic group, an aryl group or a substituted aryl group); and R3 is -H, -S(O)2H, -P(O)2OH, -N(O)OH or -P(O)2OP(O)2OH. Also disclosed are methods of treating a

subject with a neurol. condition or disease and methods of treating a subject in need of immunosuppression. The subject can be, e.g., in need of neuroprotection, in need of neurogenesis, or in need of neuritogenesis. The method can be used for immunosuppression, e.g., a subject with organ, bone marrow, or stem cell transplant or a subject with autoimmune disease. The methods comprises the step of administering to the subject an effective amount of the synthetic ganglioside represented by Structural Formula (I).

AN 2002:171915 HCAPLUS <<LOGINID::20090908>>

DN 136:210593

TI Novel synthetic gangliosides

IN Ho, Tony W.

PA Neuronix, Inc., USA

SO PCT Int. Appl., 38 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2002018401	A2	20020307	WO 2001-US27087	20010830 <--
	WO 2002018401	A3	20020822		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	AU 2001085359	A	20020313	AU 2001-85359	20010830 <--
PRAI	US 2000-654363	A1	20000901	<--	
	WO 2001-US27087	W	20010830	<--	

OS MARPAT 136:210593

OSC.G 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 13 OF 18 HCAPLUS COPYRIGHT 2009 ACS on STN

TI Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immunotherapies

AB The invention teaches methods for treating tumors and tumor metastases in a mammal comprising administering, to a mammal in need of treatment, a therapeutic amount of an antagonist sufficient to inhibit angiogenesis in combination with a therapeutic amount of anti-tumor immunotherapeutic agent, such as an anti-tumor antigen antibody/cytokine fusion protein having a cytokine and a recombinant Ig polypeptide chain sufficient to elicit a cytokine-specific biol. response.

AN 2000:573686 HCAPLUS <<LOGINID::20090908>>

DN 133:176175

TI Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immunotherapies

IN Lode, Holger N.; Reisfeld, Ralph A.; Cheresh, David A.; Gillies, Stephen D.

PA The Scripps Research Institute, USA; Lexigen Pharmaceuticals Corporation

SO PCT Int. Appl., 78 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000047228	A1	20000817	WO 2000-US3483	20000211 <--
	W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
	CA 2360106	A1	20000817	CA 2000-2360106	20000211 <--
	AU 2000032280	A	20000829	AU 2000-32280	20000211 <--
	AU 776790	B2	20040923		
	EP 1156823	A1	20011128	EP 2000-910138	20000211 <--
	EP 1156823	B1	20081029		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, AL, MK				
	BR 2000008161	A	20020528	BR 2000-8161	20000211 <--
	HU 2002000128	A2	20020529	HU 2002-128	20000211 <--
	JP 2002536419	T	20021029	JP 2000-598179	20000211 <--
	RU 2236251	C2	20040920	RU 2001-124907	20000211 <--
	CN 1192796	C	20050316	CN 2000-806134	20000211 <--
	US 7115261	B1	20061003	US 2000-502732	20000211 <--
	AT 412433	T	20081115	AT 2000-910138	20000211 <--
	ES 2313883	T3	20090316	ES 2000-910138	20000211 <--
	ZA 2001006455	A	20021106	ZA 2001-6455	20010806 <--
	NO 2001003906	A	20011009	NO 2001-3906	20010810 <--
	MX 2001008110	A	20021023	MX 2001-8110	20010810 <--
	US 20070036751	A1	20070215	US 2006-527029	20060926 <--
	US 7365054	B2	20080429		
	US 20090060864	A1	20090305	US 2008-148629	20080421 <--
PRAI	US 1999-119721P	P	19990212	<--	
	US 2000-502732	A3	20000211	<--	
	WO 2000-US3483	W	20000211	<--	
	US 2006-527029	A3	20060926		

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OSC.G 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
RE.CNT 5 THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 14 OF 18 HCAPLUS COPYRIGHT 2009 ACS on STN

TI Potentiation of immune responses with liposomal adjuvants

AB A high-integrity liposome comprising at least one stable lipid and at least one peptide-like therapeutic agent associated with said liposome, adapted for parenteral administration to an animal, including a human, and method according to manufacture and use are disclosed. Immunizing dosage forms comprising a liposome and an immunogen, wherein said liposome and immunogen are present in an immunization dose are provided. Adnl., a dosage form, including such form particularly adapted to producing an immune response, comprising a salt according to an organic acid derivative of a sterol and an immunogen wherein said organic acid derivative of a sterol and immunogen are present in an immunization dose, and method according to use is disclosed. Further, a dosage form, including such form particularly adapted to producing an immune response, comprising dimyristoylphosphatidylcholine (DMPC)/cholesterol liposomes, optionally in an aluminum hydroxide gel, and an immunogen wherein said DMPC/cholesterol and immunogen are present in an immunization dose, and method according to use is presented.

AN 2000:492029 HCAPLUS <<LOGINID:20090908>>

DN 133:109954

TI Potentiation of immune responses with liposomal adjuvants
 IN Popescu, Mircea C.; Weiner, Alan L.; Recine, Marie S.; Janoff, Andrew S.;
 Estis, Leonard; Keyes, Lynn D.; Alving, Carl R.
 PA The Liposome Company, Inc., USA
 SO U.S., 23 pp., Cont.-in-part of U.S. 5,231,112.
 CODEN: USXXAM

DT Patent
 LA English

FAN.CNT 9

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 6090406	A	20000718	US 1990-485388	19900226 <--
	US 4721612	A	19880126	US 1985-721630	19850410 <--
	JP 09040550	A	19970210	JP 1996-191707	19850411 <--
	US 4891208	A	19900102	US 1985-773429	19850910 <--
	ZA 8507576	A	19860625	ZA 1985-7576	19851001 <--
	IL 96444	A	19921201	IL 1985-96444	19851006 <--
	DD 255533	A5	19880406	DD 1985-281616	19851010 <--
	AU 8775438	A	19880111	AU 1987-75438	19870612 <--
	JP 01501622	T	19890608	JP 1987-503771	19870612 <--
	CA 1337898	C	19960109	CA 1988-584808	19881202 <--
	US 6759057	B1	20040706	US 1989-323182	19890313 <--
	AU 8941861	A	19900323	AU 1989-41861	19890824 <--
	AU 627226	B2	19920820		
	AU 8942214	A	19900323	AU 1989-42214	19890824 <--
	AU 631377	B2	19921126		
	JP 04500203	T	19920116	JP 1989-509162	19890824 <--
	CA 1334165	C	19950131	CA 1989-609463	19890825 <--
	US 5231112	A	19930727	US 1989-425727	19891023 <--
	JP 07100367	A	19950418	JP 1993-268664	19931027 <--
	JP 2568034	B2	19961225		
	US 5897873	A	19990427	US 1995-392676	19950223 <--
PRAI	US 1984-599691	B2	19840412	<--	
	US 1985-721630	A2	19850410	<--	
	US 1985-773429	A2	19850910	<--	
	US 1986-873584	B2	19860612	<--	
	US 1986-934151	B2	19861124	<--	
	US 1987-61186	B2	19870611	<--	
	US 1987-128974	B2	19871204	<--	
	US 1988-236701	B2	19880825	<--	
	US 1988-236702	B2	19880825	<--	
	US 1988-277854	B2	19881130	<--	
	US 1989-397777	B2	19890823	<--	
	US 1989-425727	A2	19891023	<--	
	JP 1985-502090		19850411	<--	
	JP 1993-268664	A3	19850411	<--	
	IL 1985-76600	A3	19851006	<--	
	WO 1987-US1402	A	19870612	<--	
	US 1989-397758	A	19890823	<--	
	WO 1989-US3657	A	19890824	<--	
	WO 1989-US3658	A	19890824	<--	
	US 1991-758587	A1	19910912	<--	
	US 1993-108822	A2	19930818	<--	
	US 1993-146463	B1	19931102	<--	

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OSC.G 39 THERE ARE 39 CAPLUS RECORDS THAT CITE THIS RECORD (41 CITINGS)
 RE.CNT 62 THERE ARE 62 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 15 OF 18 HCAPLUS COPYRIGHT 2009 ACS on STN
 TI Peptide-containing liposomes, immunogenic liposomes and methods of

preparation and use

AB A high integrity liposome comprising at least one stable lipid and at least one peptide-like therapeutic agent associated with the liposome, adapted for parenteral administration to an animal, including a human, and a method for manufacture and use are disclosed. Immunizing dosage forms comprise a liposome and an immunogen, wherein the liposome and immunogen are present in an immunization dose. Addnl., a dosage form, including such form particularly adapted to producing an immune response, comprising a salt according to an organic acid derivative of a sterol and an immunogen present in an immunization dose, and a method for use are disclosed. Further, a dosage form, including such form particularly adapted to producing an immune response, comprising dimyristolylphosphatidylcholine (DMPC)/cholesterol liposomes, optionally in an aluminum hydroxide gel, and an immunogen wherein the DMPC/cholesterol and immunogen are present in an immunization dose, and method for their use are disclosed.

AN 1999:412601 HCAPLUS <<LOGINID:20090908>>

DN 131:63430

TI Peptide-containing liposomes, immunogenic liposomes and methods of preparation and use

IN Popescu, Mircea C.; Weiner, Alan L.; Recine, Marie S.; Janoff, Andrew S.; Estis, Leonard; Keyes, Lynn D.; Alving, Carl R.

PA The Liposome Company, Inc., USA

SO U.S., 24 pp., Cont.-in-part of U.S. Ser. No. 108,822.

CODEN: USXXAM

DT Patent

LA English

FAN.CNT 9

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	US 5916588	A	19990629	US 1995-452549	19950525 <--
	US 4721612	A	19880126	US 1985-721630	19850410 <--
	JP 09040550	A	19970210	JP 1996-191707	19850411 <--
	US 4891208	A	19900102	US 1985-773429	19850910 <--
	ZA 8507576	A	19860625	ZA 1985-7576	19851001 <--
	IL 96444	A	19921201	IL 1985-96444	19851006 <--
	DD 255533	A5	19880406	DD 1985-281616	19851010 <--
	AU 8775438	A	19880111	AU 1987-75438	19870612 <--
	JP 01501622	T	19890608	JP 1987-503771	19870612 <--
	CA 1337898	C	19960109	CA 1988-584808	19881202 <--
	US 6759057	B1	20040706	US 1989-323182	19890313 <--
	AU 8941861	A	19900323	AU 1989-41861	19890824 <--
	AU 627226	B2	19920820		
	AU 8942214	A	19900323	AU 1989-42214	19890824 <--
	AU 631377	B2	19921126		
	JP 04500203	T	19920116	JP 1989-509162	19890824 <--
	CA 1334165	C	19950131	CA 1989-609463	19890825 <--
	US 5231112	A	19930727	US 1989-425727	19891023 <--
	US 5288499	A	19940222	US 1991-758587	19910912 <--
	US 6352716	B1	20020305	US 1993-108822	19930818 <--
	JP 07100367	A	19950418	JP 1993-268664	19931027 <--
	JP 2568034	B2	19961225		
	US 5897873	A	19990427	US 1995-392676	19950223 <--
PRAI	US 1984-599691	B2	19840412	<--	
	US 1985-721630	A2	19850410	<--	
	US 1985-773429	A2	19850910	<--	
	US 1986-873584	B2	19860612	<--	
	US 1986-934151	A2	19861124	<--	
	US 1987-61186	B2	19870611	<--	
	US 1987-128974	B2	19871204	<--	
	US 1988-236701	A2	19880825	<--	

US 1988-236702 B2 19880825 <--
 US 1988-277854 B2 19881130 <--
 US 1989-397777 B2 19890823 <--
 US 1989-425727 A3 19891023 <--
 US 1991-758587 A1 19910912 <--
 US 1993-108822 A2 19930818 <--
 JP 1985-502090 19850411 <--
 JP 1993-268664 A3 19850411 <--
 IL 1985-76600 A3 19851006 <--
 WO 1987-US1402 A 19870612 <--
 US 1989-397758 A 19890823 <--
 WO 1989-US3657 A 19890824 <--
 WO 1989-US3658 A 19890824 <--
 US 1993-146463 B1 19931102 <--

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OSC.G 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)
 RE.CNT 60 THERE ARE 60 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 16 OF 18 HCAPLUS COPYRIGHT 2009 ACS on STN

TI Ganglioside immunostimulating complexes and uses thereof

AB The present invention relates generally to an immunostimulating complex comprising one or more gangliosides and more particularly to an immunostimulating complex comprising at least one of the gangliosides GM2, GD2, GD3 or GT3. The immunogenic immunostimulating complex also comprises a saponin preparation, a sterol, a protein epitope, and phospholipid. The protein may be cancer specific protein, melanoma specific protein, or influenza hemagglutinin. The present invention is useful, inter alia, as a prophylactic and/or therapeutic agent in the treatment of tumors, and more particularly, melanomas.

AN 1999:7859 HCAPLUS <<LOGINID::20090908>>

DN 130:65237

TI Ganglioside immunostimulating complexes and uses thereof

IN Cox, John Cooper; Ronnberg, Bengt John Lennart; Sjolander, Sigrid Elisabet
 PA Eriksson, Lennart, Australia; CSL Limited

SO PCT Int. Appl., 40 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 9856420	A1	19981217	WO 1998-AU453	19980612 <--
W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, GW, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW				
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
CA 2293439	A1	19981217	CA 1998-2293439	19980612 <--
AU 9880035	A	19981230	AU 1998-80035	19980612 <--
AU 725342	B2	20001012		
ZA 9805140	A	19990107	ZA 1998-5140	19980612 <--
EP 1019087	A1	20000719	EP 1998-928010	19980612 <--
EP 1019087	B1	20071121		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI, CY				
NZ 501641	A	20001222	NZ 1998-501641	19980612 <--
JP 2002504101	T	20020205	JP 1999-501150	19980612 <--

US 6814981	B1	20041109	US 2000-445749	20000210 <--
HK 1026855	A1	20080606	HK 2000-106085	20000926 <--
PRAI AU 1997-7329	A	19970612	<--	
WO 1998-AU453	W	19980612	<--	

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
 OSC.G 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (8 CITINGS)
 RE.CNT 10 THERE ARE 10 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 17 OF 18 HCAPLUS COPYRIGHT 2009 ACS on STN
 TI Phase I study of R24 in patients with metastatic melanoma including evaluation of immunologic parameters
 AB R24 is a mouse IgG3 monoclonal antibody with specificity for the disialoganglioside GD3. Most human melanomas have substantial surface GD3; in addition, a significant proportion of T lymphocytes display surface GD3. In a phase I study, we have investigated the toxicity and effect on selected immunol. parameters of three dose levels of R24 given i.v. daily for five days (10 mg/m2/d, 30 mg/m2/d and 50 mg/m2/d) to patients with advanced melanoma. R24 administration neither consistently diminished nor augmented expression of delayed type hypersensitivity (DTH) skin reaction to anergy panel antigens or to a contact allergen dinitrofluorobenzene. R24 was infrequently found on tumor cells, or on lymphocytes from DTH biopsies, despite measurable serum levels of R24. The 30 mg/m2/d dose of R24 produced a statistically significant drop in peripheral blood lymphocytes on treatment Day 5. Likewise, on Day 5 there was a modest but statistically significant decrement in the proportion of circulating cells which were R24+. While there was one mixed response, there were no complete or partial tumor regressions in the R24 treated patients; there was no evident clin. benefit from the R24 therapy. The toxicity of the R24 at the higher dose levels can be very substantial. One patient, on the highest dose level, died on the 4th day of R24 treatment; in the absence of a plausible alternative explanation, a relationship of the death to the administered R24 must be considered. A precipitous drop in serum albumin coincident with R24 administration was found in all cases; this effect has not been previously reported with R24.

AN 1998:213598 HCAPLUS <<LOGINID:20090908>>
 DN 128:281605
 OREF 128:55745a,55748a
 TI Phase I study of R24 in patients with metastatic melanoma including evaluation of immunologic parameters
 AU Maguire, Henry C., Jr.; Berd, David; Lattime, Edmund C.; Mccue, Peter A.; Kim, Sarah; Chapman, Paul B.; Mastrangelo, Michael J.
 CS Department of Medicine (Division of Medical Oncology), Thomas Jefferson University, Philadelphia, PA, 19107, USA
 SO Cancer Biotherapy & Radiopharmaceuticals (1998), 13(1), 13-23
 CODEN: CBRAFJ; ISSN: 1084-9785
 PB Mary Ann Liebert, Inc.
 DT Journal
 LA English
 OSC.G 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD (5 CITINGS)
 RE.CNT 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 18 OF 18 HCAPLUS COPYRIGHT 2009 ACS on STN
 TI Anti-allergic infant formula containing gangliosides
 AB Infant formulas which include N-acetylneuraminic acid-containing gangliosides provide protection against allergies in premature, nursing, and weaned infants as well as newborn animals. Preferred gangliosides are GM3, GD3, and GT1b at concns. of 0.1-70 mg/L.
 AN 1996:202890 HCAPLUS <<LOGINID:20090908>>
 DN 124:242351

OREF 124:44689a,44692a
 TI Anti-allergic infant formula containing gangliosides
 IN Schrotten, Horst
 PA Milupa Ag, Germany
 SO Ger. Offen., 3 pp.
 CODEN: GWXXBX
 DT Patent
 LA German
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	DE 4430041	A1	19960229	DE 1994-4430041	19940824 <--
	WO 9605844	A1	19960229	WO 1995-EP3346	19950823 <--
	W: CA, JP, US				
	RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 777486	A1	19970611	EP 1995-931192	19950823 <--
	EP 777486	B1	20030416		
	EP 777486	B2	20070613		
	R: DE, FR, GB, IT				
PRAI	DE 1994-4430041	A	19940824	<--	
	WO 1995-EP3346	W	19950823	<--	
OSC.G	3	THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)			